Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Debt Repayments (2022 - 2026)

Indivior Pharmaceuticals has reported Long-Term Debt Repayments over the past 5 years, most recently at $333.0 million for Q1 2026.

  • For Q1 2026, Long-Term Debt Repayments rose 8225.0% year-over-year to $333.0 million; the TTM value through Mar 2026 reached $346.0 million, up 42.39%, while the annual FY2025 figure was $17.0 million, 92.92% down from the prior year.
  • Long-Term Debt Repayments for Q1 2026 was $333.0 million at Indivior Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $333.0 million in Q1 2026 and troughed at -$11.0 million in Q1 2023.
  • A 5-year average of $46.6 million and a median of $4.0 million in 2025 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: tumbled 97.9% in 2025 and later surged 8225.0% in 2026.
  • Year by year, Long-Term Debt Repayments stood at $5.0 million in 2022, then soared by 380.0% to $24.0 million in 2023, then skyrocketed by 891.67% to $238.0 million in 2024, then tumbled by 97.9% to $5.0 million in 2025, then soared by 6560.0% to $333.0 million in 2026.
  • Business Quant data shows Long-Term Debt Repayments for INDV at $333.0 million in Q1 2026, $5.0 million in Q4 2025, and $4.0 million in Q3 2025.